Literature DB >> 27325848

Randomized Noninferiority Trial of Telephone Delivery of BRCA1/2 Genetic Counseling Compared With In-Person Counseling: 1-Year Follow-Up.

Anita Y Kinney1, Laurie E Steffen2, Barbara H Brumbach2, Wendy Kohlmann2, Ruofei Du2, Ji-Hyun Lee2, Amanda Gammon2, Karin Butler2, Saundra S Buys2, Antoinette M Stroup2, Rebecca A Campo2, Kristina G Flores2, Jeanne S Mandelblatt2, Marc D Schwartz2.   

Abstract

PURPOSE: The ongoing integration of cancer genomic testing into routine clinical care has led to increased demand for cancer genetic services. To meet this demand, there is an urgent need to enhance the accessibility and reach of such services, while ensuring comparable care delivery outcomes. This randomized trial compared 1-year outcomes for telephone genetic counseling with in-person counseling among women at risk of hereditary breast and/or ovarian cancer living in geographically diverse areas. PATIENTS AND METHODS: Using population-based sampling, women at increased risk of hereditary breast and/or ovarian cancer were randomly assigned to in-person (n = 495) or telephone genetic counseling (n = 493). One-sided 97.5% CIs were used to estimate the noninferiority effects of telephone counseling on 1-year psychosocial, decision-making, and quality-of-life outcomes. Differences in test-uptake proportions for determining equivalency of a 10% prespecified margin were evaluated by 95% CIs.
RESULTS: At the 1-year follow-up, telephone counseling was noninferior to in-person counseling for all psychosocial and informed decision-making outcomes: anxiety (difference [d], 0.08; upper bound 97.5% CI, 0.45), cancer-specific distress (d, 0.66; upper bound 97.5% CI, 2.28), perceived personal control (d, -0.01; lower bound 97.5% CI, -0.06), and decisional conflict (d, -0.12; upper bound 97.5% CI, 2.03). Test uptake was lower for telephone counseling (27.9%) than in-person counseling (37.3%), with the difference of 9.4% (95% CI, 2.2% to 16.8%). Uptake was appreciably higher for rural compared with urban dwellers in both counseling arms.
CONCLUSION: Although telephone counseling led to lower testing uptake, our findings suggest that telephone counseling can be effectively used to increase reach and access without long-term adverse psychosocial consequences. Further work is needed to determine long-term adherence to risk management guidelines and effective strategies to boost utilization of primary and secondary preventive strategies.
© 2016 by American Society of Clinical Oncology.

Entities:  

Mesh:

Year:  2016        PMID: 27325848      PMCID: PMC5012661          DOI: 10.1200/JCO.2015.65.9557

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  66 in total

1.  Quality of reporting of noninferiority and equivalence randomized trials.

Authors:  Anne Le Henanff; Bruno Giraudeau; Gabriel Baron; Philippe Ravaud
Journal:  JAMA       Date:  2006-03-08       Impact factor: 56.272

2.  Acceptance of genetic testing for hereditary breast ovarian cancer among study enrollees from an African American kindred.

Authors:  Anita Yeomans Kinney; Sara Ellis Simonsen; Bonnie Jeanne Baty; Diptasri Mandal; Susan L Neuhausen; Kate Seggar; Rich Holubkov; Ken Smith
Journal:  Am J Med Genet A       Date:  2006-04-15       Impact factor: 2.802

3.  Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.

Authors:  A M Martin; M A Blackwood; D Antin-Ozerkis; H A Shih; K Calzone; T A Colligon; S Seal; N Collins; M R Stratton; B L Weber; K L Nathanson
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

4.  Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing.

Authors:  Jeffrey R Botkin; Ken R Smith; Robert T Croyle; Bonnie J Baty; Jean E Wylie; Debra Dutson; Anna Chan; Heidi A Hamann; Caryn Lerman; Jamie McDonald; Vickie Venne; John H Ward; Elaine Lyon
Journal:  Am J Med Genet A       Date:  2003-04-30       Impact factor: 2.802

Review 5.  Psychiatric implications of cancer genetic testing.

Authors:  April Malia Hirschberg; Gayun Chan-Smutko; William F Pirl
Journal:  Cancer       Date:  2014-09-18       Impact factor: 6.860

6.  Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.

Authors:  Nasim Mavaddat; Susan Peock; Debra Frost; Steve Ellis; Radka Platte; Elena Fineberg; D Gareth Evans; Louise Izatt; Rosalind A Eeles; Julian Adlard; Rosemarie Davidson; Diana Eccles; Trevor Cole; Jackie Cook; Carole Brewer; Marc Tischkowitz; Fiona Douglas; Shirley Hodgson; Lisa Walker; Mary E Porteous; Patrick J Morrison; Lucy E Side; M John Kennedy; Catherine Houghton; Alan Donaldson; Mark T Rogers; Huw Dorkins; Zosia Miedzybrodzka; Helen Gregory; Jacqueline Eason; Julian Barwell; Emma McCann; Alex Murray; Antonis C Antoniou; Douglas F Easton
Journal:  J Natl Cancer Inst       Date:  2013-04-29       Impact factor: 13.506

7.  Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample.

Authors:  Marc D Schwartz; Beth N Peshkin; Chanita Hughes; David Main; Claudine Isaacs; Caryn Lerman
Journal:  J Clin Oncol       Date:  2002-01-15       Impact factor: 44.544

8.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

9.  Gene-panel sequencing and the prediction of breast-cancer risk.

Authors:  Douglas F Easton; Paul D P Pharoah; Antonis C Antoniou; Marc Tischkowitz; Sean V Tavtigian; Katherine L Nathanson; Peter Devilee; Alfons Meindl; Fergus J Couch; Melissa Southey; David E Goldgar; D Gareth R Evans; Georgia Chenevix-Trench; Nazneen Rahman; Mark Robson; Susan M Domchek; William D Foulkes
Journal:  N Engl J Med       Date:  2015-05-27       Impact factor: 91.245

10.  Differences in BRCA counseling and testing practices based on ordering provider type.

Authors:  Deborah Cragun; Lucia Camperlengo; Emily Robinson; Meghan Caldwell; Jongphil Kim; Catherine Phelan; Alvaro N Monteiro; Susan T Vadaparampil; Thomas A Sellers; Tuya Pal
Journal:  Genet Med       Date:  2014-06-12       Impact factor: 8.822

View more
  40 in total

1.  Evaluation of telephone genetic counselling to facilitate germline BRCA1/2 testing in women with high-grade serous ovarian cancer.

Authors:  Erin Tutty; Lara Petelin; Joanne McKinley; Mary-Anne Young; Bettina Meiser; Victoria M Rasmussen; Rowan Forbes Shepherd; Paul A James; Laura E Forrest
Journal:  Eur J Hum Genet       Date:  2019-04-08       Impact factor: 4.246

2.  Cost-effectiveness evaluation of pre-counseling telephone interviews before face-to-face genetic counseling in cancer genetics.

Authors:  Gaëlle Collet; Nathalie Parodi; Kevin Cassinari; Zoe Neviere; Fanny Cohen; Céline Gasnier; Afane Brahimi; François Lecoquierre; Jean-Christophe Thery; Isabelle Tennevet; Elodie Lacaze; Pascaline Berthet; Thierry Frebourg
Journal:  Fam Cancer       Date:  2018-07       Impact factor: 2.375

3.  Persistent Underutilization of BRCA1/2 Testing Suggest the Need for New Approaches to Genetic Testing Delivery.

Authors:  Anne Marie McCarthy
Journal:  J Natl Cancer Inst       Date:  2019-08-01       Impact factor: 13.506

4.  Should pretest genetic counselling be required for patients pursuing genomic sequencing? Results from a survey of participants in a large genomic implementation study.

Authors:  Joel E Pacyna; Carmen Radecki Breitkopf; Sarah M Jenkins; Erica J Sutton; Caroline Horrow; Iftikhar J Kullo; Richard R Sharp
Journal:  J Med Genet       Date:  2018-12-22       Impact factor: 6.318

5.  Preferences for in-person disclosure: Patients declining telephone disclosure characteristics and outcomes in the multicenter Communication Of GENetic Test Results by Telephone study.

Authors:  Nina Beri; Linda J Patrick-Miller; Brian L Egleston; Michael J Hall; Susan M Domchek; Mary B Daly; Pamela Ganschow; Generosa Grana; Olufunmilayo I Olopade; Dominique Fetzer; Amanda Brandt; Rachelle Chambers; Dana F Clark; Andrea Forman; Rikki Gaber; Cassandra Gulden; Janice Horte; Jessica Long; Terra Lucas; Shreshtha Madaan; Kristin Mattie; Danielle McKenna; Susan Montgomery; Sarah Nielsen; Jacquelyn Powers; Kim Rainey; Christina Rybak; Michelle Savage; Christina Seelaus; Jessica Stoll; Jill E Stopfer; Xinxin Shirley Yao; Angela R Bradbury
Journal:  Clin Genet       Date:  2018-12-07       Impact factor: 4.438

6.  Female family members lack understanding of indeterminate negative BRCA1/2 test results shared by probands.

Authors:  Deborah O Himes; Deborah K Gibbons; Wendy C Birmingham; Renea L Beckstrand; Amanda Gammon; Anita Y Kinney; Margaret F Clayton
Journal:  J Genet Couns       Date:  2019-06-14       Impact factor: 2.537

7.  Randomized Noninferiority Trial of Telephone vs In-Person Disclosure of Germline Cancer Genetic Test Results.

Authors:  Angela R Bradbury; Linda J Patrick-Miller; Brian L Egleston; Michael J Hall; Susan M Domchek; Mary B Daly; Pamela Ganschow; Generosa Grana; Olufunmilayo I Olopade; Dominique Fetzer; Amanda Brandt; Rachelle Chambers; Dana F Clark; Andrea Forman; Rikki Gaber; Cassandra Gulden; Janice Horte; Jessica M Long; Terra Lucas; Shreshtha Madaan; Kristin Mattie; Danielle McKenna; Susan Montgomery; Sarah Nielsen; Jacquelyn Powers; Kim Rainey; Christina Rybak; Michelle Savage; Christina Seelaus; Jessica Stoll; Jill E Stopfer; Xinxin Shirley Yao
Journal:  J Natl Cancer Inst       Date:  2018-09-01       Impact factor: 13.506

8.  Randomized trial of proactive rapid genetic counseling versus usual care for newly diagnosed breast cancer patients.

Authors:  Marc D Schwartz; Beth N Peshkin; Claudine Isaacs; Shawna Willey; Heiddis B Valdimarsdottir; Rachel Nusbaum; Gillian Hooker; Suzanne O'Neill; Lina Jandorf; Scott P Kelly; Jessica Heinzmann; Aliza Zidell; Katia Khoury
Journal:  Breast Cancer Res Treat       Date:  2018-04-02       Impact factor: 4.872

9.  Genetic Testing in a Population-Based Sample of Breast and Ovarian Cancer Survivors from the REACH Randomized Trial: Cost Barriers and Moderators of Counseling Mode.

Authors:  Laurie E Steffen; Ruofei Du; Amanda Gammon; Jeanne S Mandelblatt; Wendy K Kohlmann; Ji-Hyun Lee; Saundra S Buys; Antoinette M Stroup; Rebecca A Campo; Kristina G Flores; Belinda Vicuña; Marc D Schwartz; Anita Y Kinney
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-09-29       Impact factor: 4.254

10.  Impact of Genetic Testing on Risk-Management Behavior of Black Breast Cancer Survivors: A Longitudinal, Observational Study.

Authors:  Claire C Conley; Monica L Kasting; Bianca M Augusto; Jennifer D Garcia; Deborah Cragun; Brian D Gonzalez; Jongphil Kim; Kimlin Tam Ashing; Cheryl L Knott; Chanita Hughes-Halbert; Tuya Pal; Susan T Vadaparampil
Journal:  Ann Surg Oncol       Date:  2019-11-01       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.